PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital

This funding round allocated in tranches, will strengthen PathoQuest’s position as a leading NGS-based biosafety CRO for the biopharmaceutical industry.

Paris, FRANCE, Tübingen, GERMANY - November 9th, 2021 - PathoQuest, a pioneer in the quality control of biologics using Next-Generation Sequencing (NGS), today announced the closing of a financing round up to €15M. This funding leverages the NGS technology in a proprietary approach to assess the viral safety and genetic characterization of biologics. It will support the development of PathoQuest's US site (Wayne, PA), the expansion of the portfolio of NGS-based quality control (QC) tests and will accelerate its growth and market share worldwide.

The funding round is led by new investors, SHS Capital (Germany), followed by Turenne Capital/SHAM (France) and a US Family Office to reinforce the support from existing shareholders, Kurma Partners (France), Verve ventures (Switzerland), Eurazeo (France), Aurinvest (France), and a strategic partner, Charles River Laboratories (USA).

“We are pleased to acquire our first investment in a French company with the participation in PathoQuest. This expands our portfolio of promising European healthcare champions. With its innovative NGS-based approach for the biosafety of biologics, PathoQuest will help biopharmaceutical companies in their quest to deliver advanced therapy medicinal products and vaccines more safely and more rapidly than ever to patients,” stated Sascha ALILOVIC, Managing Partner at SHS Capital. “To meet the leading market needs, PathoQuest is also expanding globally with a state-of-the-art facility located in Wayne, Pennsylvania, and is broadening its portfolio of NGS-based quality control solutions for the biosafety of biologics.”

“We are pleased to complete this financing round since it enables PathoQuest to further establish its position as a leader of NGS-based quality control of cell and gene therapies, vaccines and other biologics,” commented Jean-Francois Brepson, PathoQuest’s CEO. “This funding will support the company’s fast commercial development to provide faster and safer testing to replace traditional methods including animal testing, at a Good Manufacturing Practice grade.”

Life Sciences investment firm Fraser Finance ( acted as an exclusive financial advisor to PathoQuest for this transaction. Willy Mathot Avocat at Pact Avocats ( acted as legal advisor to PathoQuest. SHS was advised on the transaction by Jérôme Chapron, from the law firm Chammas & Marcheteau. Turenne/SHAM was advised by Jérôme Chapron & Jeremie Lolmede from the law firm Chammas & Marcheteau, Marc Olivier Bévierre & Anne Moore from Cepton and Julien Trelhu from Repère group.

Download the pdf file